基于免疫组织化学标准和 Lymph2Cx 的弥漫性大 B 细胞淋巴瘤患者的起源细胞分类对东南亚人群的临床影响：单中心经验和文献复习。
Clinical impact of the cell-of-origin classification based on immunohistochemistry criteria and Lymph2Cx of diffuse large B-Cell lymphoma patients in a South-east Asian population: a single center experience and review of the literature.
机构信息
Department of Haematology-Oncology, National University Health System, Singapore, Singapore.
Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.
出版信息
Expert Rev Hematol. 2019 Dec;12(12):1095-1105. doi: 10.1080/17474086.2019.1677152. Epub 2019 Oct 19.
: Previous studies in Western populations, using immunohistochemistry (IHC) methods to subtype diffuse large B-cell lymphoma (DLBCL), suggest that germinal center B-cell lymphomas (GCBs) have improved outcomes. However, data in Asians have been limited and conflicting. This study aims to evaluate the prognostic impact of cell-of-origin (COO) subtyping by IHC and Lymph2Cx in South-East Asian (SEA) DLBCL patients, and to summarize the existing literature.: A single-center retrospective analysis of 384 DLBCL patients diagnosed 2013-2018 who received Rituximab-based chemotherapy was performed. Hans and Lymph2Cx were used to assign COO and correlated with outcomes.: International Prognostic Index (IPI) score was associated with overall survival (OS) and progression-free survival (PFS). The 5-yr-OS for non-GCB versus GCB for COO by Hans was 70% versus 71% =0.39, while 5-yr-OS for ABC versus GCB for COO by Lymph2Cx was 74% versus 92% =0.19. The 5-yr-PFS for non-GCB versus GCB for COO by Hans was 65% versus 70% =0.26, while 5-yr-PFS for ABC versus GCB for COO by Lymph2Cx was 64% versus 86% =0.07.: IPI is reaffirmed to be relevant in the rituximab era. COO by Hans has no prognostic significance, while subtyping by Lymph2Cx trends toward GCBs having better PFS and OS.
: 先前使用免疫组织化学（IHC）方法对弥漫性大 B 细胞淋巴瘤（DLBCL）进行亚型分类的西方人群研究表明，生发中心 B 细胞淋巴瘤（GCBs）的预后较好。然而，亚洲人群的数据有限且存在争议。本研究旨在评估 IHC 和 Lymph2Cx 对东南亚（SEA）DLBCL 患者的细胞起源（COO）亚型分类的预后影响，并总结现有文献。: 对 2013-2018 年接受基于利妥昔单抗的化疗的 384 例 DLBCL 患者进行了单中心回顾性分析。使用 Hans 和 Lymph2Cx 来分配 COO，并与结果相关联。: 国际预后指数（IPI）评分与总生存期（OS）和无进展生存期（PFS）相关。Hans 法非 GCB 与 GCB 相比的 5 年 OS 为 70%与 71%（=0.39），而 Lymph2Cx 法 ABC 与 GCB 相比的 5 年 OS 为 74%与 92%（=0.19）。Hans 法非 GCB 与 GCB 相比的 5 年 PFS 为 65%与 70%（=0.26），而 Lymph2Cx 法 ABC 与 GCB 相比的 5 年 PFS 为 64%与 86%（=0.07）。: IPI 在利妥昔单抗时代再次被证实具有相关性。Hans 法的 COO 无预后意义，而 Lymph2Cx 法的亚型分类显示 GCBs 的 PFS 和 OS 更好。
Zotero 插件